TCI vs XFOR Comparison

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.